FEB 18, 2016 10:11 AM PST

Dramatic Remissions Seen in Immunotherapy Trial

WRITTEN BY: Julianne Chiaet

 
Dr. Stanley RiddellDramatic remissions have been seen in a cancer immunotherapy trial for patients with blood cancers. Specifically, 27 out of 29 patients with advanced blood cancer sustained remissions with this treatment. The results are preliminary as the study is ongoing at the Fred Hutchinson Cancer Research Center in Seattle.

Immunotherapy is a revolutionary approach to fighting cancer. The treatment is still experimental, so it is generally reserved for those whose cancer was resistant to other cancer-fighting treatments. The trial began in 2013, and many of the recruited patients were not expected to survive for more than a few months.

The team at Fred Hutchinson uses an immunotherapy technique called adoptive T-cell therapy. The treatment works by first taking a patient’s T-cells, a type of white blood cell. T cells have the ability to detect and attack foreign or abnormal cells. Unfortunately, cancer can exhaust and overpower T cells. In addition, tumors use an array of techniques to evade them.

After taking the T cells, the researchers then genetically engineer them with synthetic molecules called chimeric antigen receptors (CAR). The CARs enable the T cells to attack the body’s cancer cells. The army of cancer-fighting cells is grown in a lab and then given back to the patient. The therapy does not need to be repeatedly administered because T cells can continue to multiply once delivered back into the patient.

The researchers noticed dramatic remissions in the treatment of patients with two types of cancers: lymphomas and some types of leukemias. However, while the treatment shows promising results, “much like chemotherapy and radiotherapy, it’s not going to be a save-all,” said Immunotherapy researcher and oncologist Stanley Riddell. Some patients may require alternative treatments.

Ridell and his colleagues are continuously revising the T-cell therapy protocols in hopes to make the therapy more effective and reduce the harmful side effects. The side effects, sometimes serious, have included fevers, drops in blood pressure, neurological symptoms, and cytokine release syndrome. Seven patients in the study ended up in intensive care due to the side effects. Two of the study participants died. The team found that administering the lowest dose of T cells to those with the highest tumor burdens lowered the risk of serious side effects.

The researchers are now working on developing safer and easier to design T cells. It is important to note that the research has not yet been published, and has thus not been evaluated by scientists independent of the study.

Riddell shared the trial results on Sunday at the American Association for the Advancement of Science in Washington D.C.

Sources: Fred Hutchinson Cancer Research Center: Hutch News, RT America video
About the Author
  • Julianne (@JuliChiaet) covers health and medicine for LabRoots. Her work has been published in The Daily Beast, Scientific American, and MailOnline. While primarily a science journalist, she has also covered culture and Japanese organized crime. She is the New York Board Representative for the Asian American Journalists Association (AAJA). • To read more of her writing, or to send her a message, go to Jchiaet.com
You May Also Like
SEP 02, 2021
Genetics & Genomics
Study ID's New Regulatory Regions in the Human Genome
SEP 02, 2021
Study ID's New Regulatory Regions in the Human Genome
There's so much more to the human genome than just instructions for making proteins, for example, many non-coding region ...
SEP 14, 2021
Technology
Dental Implant Produces Its Own Electricity And Fights Bacteria
SEP 14, 2021
Dental Implant Produces Its Own Electricity And Fights Bacteria
The use of dental implants offers a long term, effective treatment approach for lost or missing teeth compared to method ...
SEP 15, 2021
Cardiology
Reducing Sugar in Packaged Foods May Protect Millions From Disease
SEP 15, 2021
Reducing Sugar in Packaged Foods May Protect Millions From Disease
For years, scientists have tried to learn more about whether addedor excess dietary sugars are harmful to a person's hea ...
SEP 16, 2021
Drug Discovery & Development
A shot for sore eyes: a novel injectable drug to treat age-related vision loss
SEP 16, 2021
A shot for sore eyes: a novel injectable drug to treat age-related vision loss
According to the Population Reference Bureau, 40 million people in the United States are aged 65 and older. This nu ...
SEP 27, 2021
Cancer
Inflammation Promotes Pancreatic Cancer Progression
SEP 27, 2021
Inflammation Promotes Pancreatic Cancer Progression
Inflammation occurs when the immune response, including immune cells and mediators they produce, protect you from danger ...
SEP 27, 2021
Microbiology
Rift Valley Fever's Infectious Secret is Revealed
SEP 27, 2021
Rift Valley Fever's Infectious Secret is Revealed
Rift Valley fever virus is carried by mosquitoes, and when it's passed to livestock including cattle, goats, and sheep, ...
Loading Comments...